Navigation Links
P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth
Date:10/29/2008

anage continued global political and/or economic uncertainty and disruptions, especially in the Company's significant geographical markets, as well as any political and/or economic uncertainty and disruptions due to a global or regional credit crisis or terrorist and other hostile activities; (9) the ability to successfully manage competitive factors, including prices, promotional incentives and trade terms for products; (10) the ability to obtain patents and respond to technological advances attained by competitors and patents granted to competitors; (11) the ability to successfully manage increases in the prices of raw materials used to make the Company's products; (12) the ability to stay close to consumers in an era of increased media fragmentation; (13) the ability to stay on the leading edge of innovation and maintain a positive reputation on our brands; and (14) the ability to successfully separate the Company's coffee business. For additional information concerning factors that could cause actual results to materially differ from those projected herein, please refer to our most recent 10-K, 10-Q and 8-K reports.

About Procter & Gamble

Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands, including Pampers(R), Tide(R), Ariel(R), Always(R), Whisper(R), Pantene(R), Mach3(R), Bounty(R), Dawn(R), Gain(R), Pringles(R), Folgers(R), Charmin(R), Downy(R), Lenor(R), Iams(R), Crest(R), Oral-B(R), Actonel(R), Duracell(R), Olay(R), Head & Shoulders(R), Wella(R), Gillette(R), Braun(R) and Fusion(R). The P&G community includes approximately 138,000 employees working in over 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

The Procter & Gamble Company

Exhibit 1: Non-GAAP Measures

In accordance wit
'/>"/>

SOURCE The Procter & Gamble Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Cardinal Health Reports First Quarter Results
2. uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series
3. STAAR Surgical Reports 33% Third Quarter Revenue Growth
4. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
5. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
6. LCA-Vision Reports Third Quarter 2008 Financial Results
7. Universal Health Services, Inc. Reports 2008 Third Quarter Results
8. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
9. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
10. WellPoint Reports Third Quarter 2008 Results
11. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...t. Jude Children,s Research Hospital have demonstr...monia following influenza. They found that the ant...bacteria by inhibiting their protein synthesis, ar...ent with the "beta-lactam" antibiotic ampicillin, ... The finding is important because pneumonia, rathe...
(Date:1/8/2009)..., Jan. 8 Hanger Orthope...nce that throughout the fourth quarter of 2008 it ...er, Rocky Mountain Orthotic-Prosthetics Center, Ri...First Coast Orthotics & Prosthetics, and Ortho...ions add patient care centers to existing markets ...
(Date:1/8/2009)...ed Acquisition in 2009 Continues Growth Trend , ...stCall/ -- IPC The Hospitalist Company, Inc. (Nasd...cian group practice company, announced today that ...t Acute Care Consultants, Inc. (MACC) in St. Louis...xpansion in the St. Louis market, where IPC has es...
(Date:1/8/2009)... Md., Jan. 8 /PRNewswire-Asia/ -- Chindex Internat...pany"), a leading independent American,provider o...People,s Republic,of China, today announced that ...a Conference, to be held in Shanghai on January 12...onference will be held at the Pudong Shangri-,La ...
Breaking Medicine News(10 mins):Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2
...stem, will invest $20 million to establish the wor...India, to provide stem cells for transplant surgeo... a 10% equity stake in this venture and two seats ...nt guidelines are followed, Said company president...
...d occupy greater priority in India due to the ever...chewing practices. There has been a considerable i...n men. // In India and Sri Lanka, where chewing t...verse smoking is practiced, there is a striking in...
...s had a sensitive tooth at some point of their lif... tooth is worn out' or 'you brush in a hard way, s...the Leeds University have come out with a solution... memory. The researchers have developed a solution...
...fund a study which helps to understand the benefit... given to breast cancer patients to ease the pain ...es. The study is to be carried out by Researchers ...will be comparing the three complementary therapy ...
Other Medicine News:Health News:Dental health neglected by over 60 % of Indians 2
(Date:1/7/2009)...PRNewswire/ -- ImQuest Life Sciences announced tod... to the Food and Drug Administration to initiate h...e HIV inhibitor IQP-0410. ImQuest anticipates init...of 2009. IQP-0410 is a novel small molecule inhibi... reverse transcriptase inhibitor (NNRTI). The comp...
(Date:1/7/2009)...uary 7 Circassia Ltd, a specialty,...critical care, today,announced that following suc...s ToleroMune(R) anti-allergy technology, the compa...rther phase II clinical trial in cat allergy. The,... 120 patients with confirmed,cat allergies, and a...
(Date:1/6/2009)...RNewswire/ -- In recent controlled studies conduct..., scientists found that the patented ingredient in...y proven ingredient to increase levels of nitric o...trate/nitrate (NOx) in human subjects. , , Nitr...ease in blood flow to the skeletal muscles. This ...
(Date:1/6/2009)... Cequent Pharmaceuticals, a pionee...RNAi-based treatments to prevent and treat human d...mpleted a successful toxicology study of its candi...peutic targeting the primary oncogene (beta-cateni.... FAP is an inherited gastrointestinal disease tha...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 23563 1Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 23563 2Gene Activity May Explain Deadlier Breast Cancers Among Younger Women 23563 3China Medicine Releases White Paper on Developing Recombinant Aflatoxin Detoxifizyme 23558 1China Medicine Releases White Paper on Developing Recombinant Aflatoxin Detoxifizyme 23558 2Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President Global Supply Chain and Sustainment Engineering 6445 1Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President Global Supply Chain and Sustainment Engineering 6445 2Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President Global Supply Chain and Sustainment Engineering 6445 3Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 1Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 2Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 3Orexigen 28R 29 Initiates Second Phase IIb Empatic 28TM 29 Trial on Schedule 2602 4
...ETROIT, April 16, 2007 /PRNewswire/ -- Karmanos Ca... on two research,studies investigating racial disp... American Association of Cancer Research,annual me...h endometrial or ovarian cancer, on,average, live ...ed,by Veronica Schimp, D.O., assistant professor o...
...nespimycin Shown to Have No Effect on QTc Interval...Kosan,Biosciences Incorporated today presented saf...its lead Hsp90 inhibitor,tanespimycin (KOS-953). ...nts was conducted in four Phase 1 trials of tanesp... in more than 85,patients. Tanespimycin was found ...
Other Medicine Technology:Karmanos Physician-Scientists Examine Racial Disparities in,Patients with Gynecologic Cancer 2Karmanos Physician-Scientists Examine Racial Disparities in,Patients with Gynecologic Cancer 3Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 2Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 3Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR 4
...channel within a 12.1mm insertion tube. It featur...d image for improved reliability, an electronic be...5 and 5.0mhz transducer for deeper ultrasound imag...ical orientation and vascular evaluation during re...
...of diagnosis by using the Convex Scanning method. ...od flow by using the Color Flow Mapping and Color ...rated and the balloon fixation has improved. Those...curate techniques. The FG-36UX expands the possibi...
ACL 1000 is an affordable solution for low volume workloads, or as a backup analyzer. The test menu includes a variety of clotting assays, such as Lupus and APCR-V Leiden. The ACL 1000 also offers ba
The SYNCHRON CX5 Delta takes the automation and versatility of the SYNCHRON CX®4 Delta and adds the benefit of electrolyte testing. It's the ideal full-service clinical chemistry system for the l
Medicine Products: